End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
18.05 USD | +4.64% | +6.18% | +18.75% |
28/06 | Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU | MT |
28/06 | AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment | MT |
Chart: Technical Analysis
Technical Rankings Surperformance
Short Term Timing | |
---|---|
Middle Term Timing | |
Long Term Timing | |
RSI | |
Bollinger Spread | |
Unusual Volumes |
- Stock Market
- Equities
- ABBV Stock
- ABBVD Stock
- Charts AbbVie Inc.